ERBB2 and neoplasm: In addition, inhibiting the enzymes responsible for sNKG2D ligands, including ADAM10 and ADAM17 (71–76), with specific compounds, would push the balance toward γδT-cell activation; along this line, the combination of stimulating molecules, such as bisphosphonates, and therapeutic tumor-targeting antibodies, as the anti-CD20 rituximab or the anti-ERBB2 trastuzumab, should improve the efficacy of γδT-cell anti-tumor effect (56, 58).